

Bradykinin Kallidin and Kallikrein

Supplement

Editor E.G.Erdös



Springer-Verlag Berlin Heidelberg New York

Bradykinin, Kallidin and Kallikrein

Supplement

Contributors

K. D. Bhoola · W. G. Clark · R. W. Colman · E. G. Erdös
F. Fiedler · T. L. Goodfriend · L. M. Greenbaum
A. R. Johnson · M. Lemon · A. P. Levitskiy
H. S. Margolius · R. Matthews · I. H. Mills · H. Z. Movat
C. E. Ody · T. S. Paskhina · J. J. Pisano
J. M. Stewart · R. C. Talamo · A. Terragno
N. A. Terragno · R. Vogel · P. E. Ward · P. Y. Wong

Editor

E. G. Erdös



Springer-Verlag Berlin Heidelberg New York 1979

Professor Dr. ERVIN G. ERDÖS, Departments of Pharmacology, and Internal Medicine. The University of Texas, Southwestern Medical School, 5323 Harry Hines Blvd., Dallas TX 75235/USA

With 83 Figures

This volume completes „Handbuch der experimentellen Pharmakologie, Vol. XXV“, published in 1970.

ISBN 3-09356-7 Springer-Verlag Berlin Heidelberg New York
ISBN 0-09356-7 Springer-Verlag New York Heidelberg Berlin

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use, a fee is payable to the publisher, the amount of the fee to be determined by agreement with the publisher.

© by Springer-Verlag Berlin Heidelberg 1979.

Printed in Germany.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Typesetting, printing, and bookbinding: Brühlsche Universitätsdruckerei, Lahn-Gießen. 2122/3130-543210

Handbook of Experimental Pharmacology

Continuation of Handbuch der experimentellen Pharmakologie

Vol. XXV Supplement

Editorial Board

G.V.R. Born, Cambridge · A. Farah, Rensselaer, New York
H. Herken, Berlin · A.D. Welch, Memphis, Tennessee

Advisory Board

S. Ebashi · E. G. Erdös · V. Erspamer · U. S. von Euler · W. S. Feldberg
G. B. Koelle · O. Kraye · M. Rocha e Silva · J. R. Vane · P. G. Waser
W. Wilbrandt

Preface

Volume XXV of the Handbook of Experimental Pharmacology series entitled "Bradykinin, Kallidin, and Kallikrein" was published in 1970. My aim in editing this volume of the series is not to replace, but to update the 1970 edition. During the decade preceding the publication of Vol. XXV, the existence of kinins and kallikreins gained acceptance, the protein components of the system were purified and characterized and the peptides were synthesized. Even after these accomplishments, interest in the subject has not abated, but has increased substantially. We have learned a great deal about the role that components of the kallikrein-kinin system play in other systems and about the immensely complex and intricate interactions in blood. Directly or indirectly, kallikrein and kinins affect the coagulation of blood, the activation of complement, and the generation of angiotensin. Kinins release or modulate the actions of other agents, including prostaglandins, histamine, and catecholamines. Inhibitors of kallikrein or kininase II are employed, for example, in extracorporeal circulation or in hypertension. Kallikrein, kinins, and kininases, present in urine, were described first in 1925 and 1954, but have been ignored for decades. These substances are now studied extensively because of their possible role in blood pressure regulation. The evidence that kinins have a metabolic function is also increasing. The abundance of active components of the system in genital organs suggests a role in the fertilization process.

The book is organized into chapters which bear upon these issues. The first four chapters discuss kininogenases, the enzymes which release kinins and their inhibitors. Plasma kallikrein, its substrates and its inhibitors and the interrelationships with other blood-borne systems are reviewed in the first chapter. This is followed by a discussion of kininogenases in blood cells including acid kininogenases which form an alternate kinin system.

Reviews of the extensive studies on the structure of glandular kallikreins and their inhibitors are next, summarizing the achievements of a very enlightening period of protein research.

The next section deals with kinins. Structure-activity studies on peptides of the kinin system and on bradykinin potentiators have lead to the synthesis of effective kininase II inhibitors and hopefully, in the future, will lead to the development of specific kinin antagonists. Free, naturally occurring bradykinin and related peptides are next. If we wish to understand the actions of kinins, we must learn about their sites of action and we must be able to assay them accurately and in minute quantities. Chapters on bradykinin receptors and on radioimmunoassay contribute an up-to-date review of these problems. The actions of kinins and kallikrein in the central nervous system and other tissues are described next. Some of the investigations

described here may be only initial observations, but might later open new areas of research. Among the most intriguing aspects of research on kinins are studies of their indirect actions, especially their interrelationships with prostaglandins (Chap. XI). Kinins are not stable in the organism; they are rapidly inactivated in blood and kininases in tissues limit their actions. The functioning of kininase I as an anaphylatoxin inactivator and kininase II as the angiotensin I converting enzyme emphasizes the importance of these proteins.

Glandular kallikrein and urinary kallikrein have been scrutinized by many researchers since excretion of the latter seems to be connected with hypertension. Chapters XIII, XIV, and XV describe the results of experimental work on glandular, renal, and urinary kallikrein in laboratory animals and man. Kinins may have a more important role in pathological than in physiological processes, as surveyed in Chap. XVI. The final chapter summarizes the extensive literature published in Russian because it is not easily accessible to readers outside of the U.S.S.R.

In 1966 I wrote in a review (*Adv. Pharmacol.* 4, 1-90) "... the status of kinins somewhat resembles that of acetylcholine or histamine. Bradykinin may never become a therapeutically important agent. Nevertheless, if kinins play a significant role in some physiological or pathological conditions, agents which block the effects or inhibit their enzymic metabolism would be of prime importance." Since half of the second prediction seems to be fulfilled by the development of kininase II inhibitors, we may look forward to finding kininase I inhibitors that work in the whole organism, and to the development of active kinin blocking agents.

Finally, I mention with deep regret that Professor EUGEN WERLE is no longer with us; thus he can not witness the exciting developments in the field where he achieved so much, so early, and so far ahead of others.

Dallas, June 1979

E. G. ERDÖS

List of Contributors

- K.D. BHOOLA, Department of Pharmacology, University of Bristol, The Medical School, University Walk, GB-Bristol BS8 1TD
- W.G. CLARK, Department of Pharmacology, University of Texas, Southwestern Medical School, 5323 Harry Hines Blvd., Dallas, TX 75235/USA
- R.W. COLMAN, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104/USA
- E.G. ERDÖS, Departments of Pharmacology and Internal Medicine, University of Texas, Southwestern Medical School, 5323 Harry Hines Blvd., Dallas, TX 75235/USA
- F. FIEDLER, Abteilung für Klinische Biochemie in der Chirurgischen Klinik, Nußbaumstr. 20, D-8000 München 2
- T.L. GOODFRIEND, Department of Internal Medicine and Pharmacology, Veterans Admin. Hospital, Madison, WI 53705/USA
- L.M. GREENBAUM, Departments of Pharmacology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032/USA
- A.R. JOHNSON, Department of Pharmacology, University of Texas, Southwestern Medical School, 5325 Harry Hines Blvd., Dallas, TX 75235/USA
- M. LEMON, Department of Pharmacology, University of Bristol, The Medical School, University Walk, GB-Bristol BS8 1TD
- A.P. LEVITSKIY, Institute of Biological and Medical Chemistry, USSR Academy of Medical Sciences, Pogodinskaya ul. 10, USSR-Moscow 119121
- H.S. MARGOLIUS, Department of Pharmacology, Medical University of South Carolina, 80 Barre Street, Charleston, SC 29401/USA
- R. MATTHEWS, Department of Pharmacology, University of Bristol, The Medical School, University Walk, GB-Bristol BS8 1TD
- I.H. MILLS, University of Cambridge, Clinical School, Department of Medicine, Level 5, Addenbrooke's Hospital, Hills Road, GB-Cambridge CB2 2QQ
- H.Z. MOVAT, University of Toronto, Department of Pathology, Medical Sciences Building, Toronto 5, Ont. M5S 1A8/CDN
- C.E. ODYA, Department of Health, Education, and Welfare, National Heart, Lung, and Blood Institute, Bldg. 10, Room 5N307, Bethesda, MD 20014/USA
- T.S. PASHKINA, Institute of Biological and Medical Chemistry, USSR Academy of Medical Sciences, Pogodinskaya ul. 10, USSR-Moscow 119121
- J.J. PISANO, Department of Health, Education, and Welfare, Public Health Service, National Heart, Lung, and Blood Institute, Bethesda, MD 20014/USA
- J.M. STEWART, Department of Biochemistry, University of Colorado, Medical Center, 4200 East Ninth Ave., Denver, CO 80220/USA

- R.C. TALAMO, Department of Pediatrics, The Johns Hopkins Hospital, Baltimore, MD 21205/USA
- A. TERRAGNO, Department of Pharmacology, The University of Tennessee Center for the Health Sciences, 800 Madison Ave., Memphis, TN 38163/USA
- N.A. TERRAGNO, Department of Pharmacology, The University of Tennessee Center for the Health Sciences, 800 Madison Ave., Memphis, TN 38163/USA
- R. VOGEL, Biochemische Analytik 78, Nußbaumstr. 20, D-8000 München 2
- P.E. WARD, Department of Pharmacology, University of Texas, Southwestern Medical School, 5323 Harry Hines Blvd., Dallas, TX 75235/USA
- P.Y. WONG, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104/USA

Contents

I. The Plasma Kallikrein-Kinin System and Its Interrelationship With Other Components of Blood. H. Z. MOVAT. With 24 Figures

A. Introduction	1
B. Initiation of Kinin Formation and Its Relation to Blood Clotting – Early Views and Concepts	2
I. Permeability Globulin PF/dil, and Its Relation to the Contact Phase of Blood Coagulation and to Kinin Formation	2
II. The Concept of Two Kinin Systems	6
C. Factor XII (Hageman Factor)	7
I. Isolation and Purification	8
II. Physico-Chemical Properties	14
III. Activation of Factor XII	15
1. Mechanism of Activation	15
2. Activators of Factor XII	22
3. Contact Activation	23
IV. Substrates of Factor XII	28
V. Inhibition of Factor XII	29
D. Prekallikrein and Kallikrein	30
I. Isolation and Purification	30
II. Physicochemical Properties	35
III. Activation of Prekallikrein to Kallikrein	37
IV. Assays of Prekallikrein and Kallikrein	39
V. Complexing of Prekallikrein and Kallikrein in Plasma	40
VI. Prekallikrein Deficiency	43
VII. Inhibition of Kallikrein	43
VIII. Functions of Kallikrein	44
E. Kininogens	44
I. Isolation and Purification	44
1. Low Molecular Weight Kininogen of Human Plasma	44
2. High Molecular Weight Kininogen of Human Plasma	46
3. Kininogens of Animal Plasmas	50
II. Physicochemical Properties	52
III. Cleavage of Kininogens	54
IV. Kininogen Deficiency	56
F. The Fibrinolytic System	56
I. Activation	56
II. Plasminogen and Plasmin	59

1. Isolation and Purification	59
2. Physicochemical Properties	60
3. Activation of Plasminogen to Plasmin	61
4. Effect on the Kinin System	61
III. Inhibition of Plasmin	62
IV. Plasminogen-Independent Fibrinolysis	62
G. Kinin Generation by Neutrophil Leukocytes	63
1. Mechanisms of Lysosomal Enzyme Release From Neutrophils	63
2. Proteases of Neutrophil Leukocyte Lysosomes	64
3. Interaction Between Neutrophil Proteases and Plasma Substrates	66
H. Plasma Proteinase Inhibitors	67
I. Concluding Remarks	70
References	71

II. Kininogenases of Blood Cells (Alternate Kinin Generating Systems).

L. M. GREEN-BAUM. With 4 Figures

A. Introduction	91
B. The Leukokinin Generating System	91
I. Chemistry of the Leukokinins	92
II. Pharmacologic Properties of Leukokinins	92
III. Leukokinin Forming Enzyme	94
1. Overall Properties	94
2. Measurement of Activity of Leukokinin-Forming Enzyme	94
3. Sources of Leukokinin-Forming Enzyme	94
4. pH Optima of the Leukokinin-Forming Enzyme	96
5. Inhibitors of Leukokinin-Forming Enzyme and Its Differentiation From Plasma Kallikrein	97
6. Pepstatin	97
7. Leukokininogen	97
8. Role of Leukokinins in Inflammation and Neoplastic Disease	98
C. Human Basophil Kinin Generating System	99
I. Characteristics of the Kallikrein of Anaphylaxis	99
D. Human Neutrophil Kininogenase	99
E. Mast Cell Kininogenase	100
F. Neoplastic Cell Kininogenase	100
G. Splenic Kininogenase	100
Summary	100
References	101

III. Enzymology of Glandular Kallikreins. F. FIEDLER. With 1 Figure

A. Introduction	103
B. Assay of Glandular Kallikreins	103

C. Glandular Kallikreins of the Pig	105
I. Porcine Pancreatic Prekallikrein	105
II. Porcine Pancreatic Kallikrein B'	106
III. Kallikrein From Autolyzed Porcine Pancreas	106
1. Isolation	106
2. Heterogeneity	108
3. Optical Properties	109
4. Molecular Weight	109
5. Amino Acid and Carbohydrate Composition	109
6. End Groups and Composition From Polypeptide Chains	111
7. Amino Acid Sequence	111
8. Stability	113
9. Hydrolysis of Amino Acid Esters	113
10. Protein and Peptide Hydrolysis	115
11. Low Molecular Weight Reversible Inhibitors and Activators	118
12. Active-Site Directed Reagents	119
13. Mechanism of Catalysis	120
IV. Porcine Submandibular Kallikrein	120
1. Isolation and Molecular Aspects	120
2. Catalytic Properties	121
V. Porcine Urinary Kallikrein	123
1. Isolation and Molecular Aspects	123
2. Catalytic Properties	123
VI. Relationships of the Porcine Glandular Kallikreins	123
1. Various Forms of Pancreatic Kallikrein	123
2. Pancreatic, Submandibular, and Urinary Kallikreins	124
D. Glandular Kallikreins of Man	125
I. Human Pancreatic Kallikrein	125
II. Human Salivary Kallikrein	125
1. Isolation and Molecular Aspects	125
2. Catalytic Properties	128
III. Human Urinary Kallikrein	128
1. Isolation and Molecular Aspects	128
2. Catalytic Properties of the Preparations of MORIYA and Co-Workers	129
3. Catalytic Properties of the Preparation of HIAL et al.	130
IV. Comparison of the Three Human Glandular Kallikreins	132
E. Glandular Kallikreins of the Rat	133
I. Rat Pancreatic Kallikrein	133
II. Rat Submandibular Kallikrein	135
III. Rat Urinary Kallikrein	136
1. Isolation and Molecular Aspects	136
2. Catalytic Properties	137
IV. Comparison of Rat Glandular Kallikreins	139
F. Glandular Kallikreins of Other Species	140
I. Mouse Submaxillary Kallikrein	140
II. Cat Submaxillary Kallikrein	143

III. Dog Pancreatic Kallikrein	143
IV. Horse Urinary Kallikrein	143
1. Isolation and Molecular Aspects	143
2. Catalytic Properties	145
3. Low Molecular Weight Inhibitors	148
V. Rabbit Urinary Kallikrein	149
VI. Guinea Pig Coagulating Gland Kallikrein	149
G. Glandular Kallikreins as a Distinct Group of Related Enzymes	150
I. Glandular Kallikreins as Acid Glycoproteins Belonging to the Serine Proteinases of Pancreatic Type	150
II. Glandular Kallikreins as Serine Proteinases	151
III. Glandular Kallikreins as Kininogenases Which Release Kallidin	152
IV. Glandular Kallikreins as Enzymes Highly Specific in Interactions With Proteins	152
V. Glandular Kallikreins as Arginine-Specific Hydrolases With Pronounced Secondary Specificity	153
References	154

IV. Kallikrein Inhibitors. R. VOGEL. With 3 Figures

A. Introduction	163
B. Methods and Definitions	164
I. Methods of Isolation	164
II. Methods of Determination	164
III. Labeling	166
IV. Immunologic Methods	166
V. Estimation of Inhibitor Capacity	166
VI. Determination of Reactive Site	166
VII. Kinetics of Complex Binding Reaction	167
C. Protein of Inhibitors of Kallikrein	167
I. Polyvalent Bovine Proteinase Inhibitor (BPTI)	167
1. Isolation	167
2. Three-Dimensional Structure of BPTI	168
3. Structure-Dependent Properties	168
4. The Reactive Site	171
5. Modification of the Reactive Site	172
6. Conformational Studies of the BPTI Complex With Trypsin and Chymotrypsin	173
7. Synthesis of Models of the Reactive Site	176
8. Synthesis of BPTI	176
9. Inhibition Spectrum	177
10. Physiology	181
II. BPTI-Related Kallikrein Inhibitors in Various Animal Phyla	184
1. Cnidaria: Trypsin-Kallikrein Inhibitor in Sea Anemones	184
2. Gastropoda: Kallikrein Inhibitor of Helix Pomatia	185
3. Mollusca: Kallikrein Inhibitor From Cuttle-Fish	188
4. Kallikrein Inhibitors in Reptilia (Proteroglypha)	189

III. Kallikrein Inhibitors of Animal Origin of HMW and/or Not Fully Characterized	190
1. Kallikrein Inhibitors in Annelida	190
2. Kallikrein Inhibition by Egg White	191
3. Kallikrein Inhibitor in Rat Submaxillary Gland	192
4. Rat Kidney Tubule Kallikrein-Specific Inhibitor	193
IV. Protein Proteinase Inhibitors in Plants	193
1. Soybean Inhibitor (Kunitz)	193
2. Leguminosae: Inhibitors of Other Species	198
3. Kallikrein Inhibitors in Solanaceae	200
V. Peptide Inhibitors of Kallikrein From Microorganisms	203
VI. Synthetic Model Inhibitors of Kallikreins	204
1. Di-Isopropyl-Fluorophosphate (DFP), (Serine Proteinase Specific)	204
2. Chloromethyl Ketones: Selective His-Alkylating Agents	204
3. Compounds Resembling the Aromatic Residues of the Synthetic Kallikrein Substrates (Arg)	205
4. Inactivation by Conversion to Acyl-Enzyme. Inhibition With Aliphatic and Aromatic Acid Esters	206
5. Other Compounds	207
VII. Influence of Metal Ions on Kallikrein	207
References	207

V. Chemistry and Biologic Activity of Peptides Related to Bradykinin. J. M. STEWART.
With 2 Figures

A. Introduction	227
B. Structure-Activity Relationships of Bradykinin Analogs	236
I. Effects of Bradykinin Analogs on Isolated Rat Uterus	236
II. Effects of Bradykinin Analogs on Intestinal Smooth Muscle	242
III. Effects of Bradykinin Analogs on Vascular Permeability	243
IV. Effects of Bradykinin Analogs on Blood Pressure	244
V. Structure-Activity Relationships in Other Assays	247
C. Antagonists of Bradykinin Action	248
D. Potentiators of Responses to Kinins	249
I. Naturally Occurring Bradykinin-Potentiating Peptides	250
II. Synthetic Bradykinin-Potentiating Peptides	256
III. Potentiation of the Bradykinin Response by Enzymes	259
IV. Potentiation by Chelating Agents	259
E. Conformation of Bradykinin in Solution	260
F. Chemical Synthesis of Bradykinin, Bradykinin Analogs, and Bradykinin-Potentiating Peptides	262
I. Solution Synthesis of Bradykinin and Related Peptides	262
II. Solid-Phase Synthesis of Bradykinin and Related Peptides	263
III. Synthesis of Bradykinin-Potentiating Peptides	264
IV. Purity of Synthetic Peptides	265
References	265

VI. Kinins in Nature. J.J. PISANO

A. Bradykinins	273
B. Tachykinins	278
C. Putative Kinins	278
D. Comparative Studies of Plasma Kallikrein-Kinin Systems	280
E. Concluding Remarks	281
References	282

VII. Bradykinin Receptors. C.E. ODYA and T.L. GOODFRIEND

A. Introduction	287
B. Experimental Approaches	287
I. Direct Binding Studies	287
II. Modification of Receptors and Responses in Vitro	289
1. General	289
2. Potentiators	291
3. Inhibitors	291
III. Modification of Receptors and Responses in Vivo	293
IV. Receptor-Effector Coupling	293
1. Ions	293
2. Prostaglandins	294
3. Cyclic Nucleotides	295
V. Structure-Activity Relationships, Physical Measurements, and Receptor Models	296
References	296

VIII. Bradykinin Radioimmunoassay. R.C. TALAMO and T.L. GOODFRIEND

Introduction	301
A. Preparation of Subjects	301
B. Preparation and Preservation of Samples	303
C. Induction of Antibodies	304
D. Labeled Antigens	305
E. Reaction Conditions	305
F. Interpretation of Data	306
G. Applications of the Radioimmunoassay	307
References	307

IX. Kinins and the Peripheral and Central Nervous Systems. W.G. CLARK

A. Introduction	311
B. Use of Bradykinin in Conscious Animals for Inducing Pain and for Assess- ment of Analgesic Activity	312

C. Cardiovascular Reflex Responses in Anesthetized Animals After Administration of Bradykinin	314
D. Interactions Between Bradykinin and Prostaglandins	317
I. Algesic Effects of Prostaglandins	317
II. Enhancement of Bradykinin Potency by Co-Administration of Prostaglandins	317
III. Release of Prostaglandins by Bradykinin	318
IV. Inhibition of Bradykinin-Induced Effects by Nonsteroidal Anti-Inflammatory Agents and Prostaglandin Antagonists	319
1. Inhibition of Prostaglandin Release	320
2. Inhibition of Other Bradykinin-Induced Effects	320
V. Conclusions	321
E. Neurophysiologic Studies in Which Bradykinin was Used as the Initial Stimulus	322
I. Paravascular Pain Receptors	322
II. Primary Afferent Fibers	323
III. Dorsal Horn	326
IV. Afferent Spinal Pathways	330
V. Brainstem	330
VI. Thalamus	332
VII. Cortex	333
F. Direct Application of Kinins to the Nervous System	333
I. Autonomic Ganglia and Postganglionic Nerves	333
II. Spinal Cord	335
III. Brain	335
1. Behavioral Responses	338
2. Cardiovascular Responses	339
3. Effects on Brain Amines	341
4. Miscellaneous Effects	342
5. Interactions With Drugs	343
G. Kallikrein-Kinin System in the Brain	345
I. Kininases	345
II. Kininogenases	346
III. Kinin-Like Activity	347
References	347

X. Effects of Kinins on Organ Systems. A. R. JOHNSON. With 10 Figures

A. Introduction	357
B. Effects on the Cardiovascular System	357
I. Cardiac Effects	357
II. Cardiac Nerves	359
III. Vascular Effects	360
IV. Vascular Permeability	364
C. Kinins and Inflammation	367

D. Kinins in Exercise and Stress	369
I. Catecholamines	369
II. Hypoxia	371
E. Effects on the Lung	372
I. Pulmonary Circulation	373
II. Pulmonary Edema	373
III. Airway Smooth Muscle	374
IV. Secretion	375
V. Asthma and Allergic Reactions	376
F. Effects on Gastrointestinal Function	376
I. Smooth Muscle	377
II. Vascular Effects	378
III. Absorption	379
IV. Cell Proliferation	380
V. Kinins and Diseases of the Gastrointestinal Tract	381
G. Effects on Reproduction	382
I. Influence of Sex Hormones	382
II. Parturition	384
III. Smooth Muscle	384
IV. Lactation	385
V. Spermatogenesis	385
VI. Sperm Motility	386
H. Epilogue	387
References	388

XI. Release of Vasoactive Substances by Kinins. N.A. TERRAGNO and A. TERRAGNO
With 6 Figures

A. Introduction	401
B. Bradykinin-Prostaglandin Interactions	401
I. Kidney	404
II. Isolated Blood Vessels	408
III. Pregnant Uterus	409
1. Contribution of Prostaglandins to Uterine Blood Flow	410
2. Stimulation of Intrauterine Prostaglandins by Kinins	410
IV. Umbilical Blood Vessels and Ductus Arteriosus	412
C. Release of Other Vasoactive Substances	415
I. Catecholamines	415
II. Histamine	417
III. Serotonin	418
IV. Antidiuretic Hormone	420
References	421

XII. Kininases. E.G. ERDÖS. With 10 Figures

A. Kininase I	428
I. Purification of the Enzyme	428

II. Inhibition	432
III. Kininase I in Pathological Conditions	433
B. Other Kininases	434
I. Undifferentiated Kininases	434
II. Low Molecular Weight Carboxypeptidase-Type Kininases	436
III. Kininase in the Central Nervous System	436
IV. Distribution of Kininases	438
V. Purified Proteases as Kininases	438
C. Kininase II: Angiotensin I Converting Enzyme	438
I. Background	439
II. Distribution of Kininase II	442
1. Endothelial Cells	442
2. Other Types of Cells	444
3. Soluble Enzyme	446
4. Kininase II in Developing Tissues	447
III. Specificity of Kininase II	447
IV. Properties of Kininase II	452
V. Antibody to Kininase II	457
VI. Kininase II in Pathological Conditions	457
VII. Converting Enzymes Which are Not Kininases	458
VIII. Inhibition in Vitro	459
IX. Inhibition of Kininase II in Vivo	461
D. Conversion of Kallidin to Bradykinin	468
E. Functions of Kininases	469
References	471
Note Added in Proof	486
References	487

XIII. Kallikrein in Exocrine Glands. K. D. BHOOLA, M. LEMON, and R. MATTHEWS

A. Historical Review	489
B. Tissue Content and Secretory Control	489
I. Gland Content of Pancreatic Kallikrein	490
II. Control of Pancreatic Kallikrein Secretion	491
III. Gland Content of Salivary Kallikrein	492
IV. Control of Salivary Kallikrein Secretion	495
C. Subcellular Distribution	503
I. Subcellular Distribution of Submandibular Kallikrein	503
II. Subcellular Distribution of Pancreatic Kallikrein	507
D. Cellular Location	508
I. Localization of Kallikrein in Rat Submandibular Gland	508
II. Localization of Kallikrein in Cat Submandibular Gland	509
III. Localization of Kallikrein in Guinea-Pig Submandibular Gland	512
E. Ontogenic Change and Hormonal Influence	513
F. Recent Views on Functional Role	515
References	518